

0001178913-24-0037826-K Sol-Gel Technologies Ltd. 2024112020241120092629092629092629 0 0001178913-24-003782 6-K 3 20241120 20241120 20241120 Sol-Gel Technologies Ltd. 0001684693 2834 000000000 L3 1231 6-K 34 001-38367 241478443 7 GOLDA MEIR ST. WEIZMANN SCIENCE PARK NESS ZIONA L3 7403648 97289313433 7 GOLDA MEIR ST. WEIZMANN SCIENCE PARK NESS ZIONA L3 7403648 6-K 1 zk2432365.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORMÂ 6-K Â Report of Foreign Private Issuer Pursuant to RuleÂ 13a-16Â orÂ 15d-16 Under the Securities Exchange Act of 1934 Â For the month of November 2024 Â Commission File Number 001-38367 Â SOL-GEL TECHNOLOGIES LTD. (Translation of registrantâ€™s name into English) Â 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executive offices) Â Indicate by check mark whether the registrant files or will file annual reports under cover FormÂ 20-FÂ or FormÂ 40-F. Â FormÂ 20-F âˆˆÂ Â Â Â Â Â Â Â Â FormÂ 40-FÂ âˆˆÂ Indicate by check mark if the registrant is submitting the FormÂ 6-KÂ in paper as permitted by RegulationÂ S-TÂ Rule 101(b)(1):Â Â Â âˆˆÂ Indicate by check mark if the registrant is submitting the FormÂ 6-KÂ in paper as permitted by RegulationÂ S-TÂ Rule 101(b)(7):Â Â Â âˆˆ

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K Â On November 20, 2024Â the Company issued a press release entitled â€œSol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement". Attached hereto is the following exhibit: Exhibit 99.1Â Â Â Â Â Â Â Â Â Press release dated November 20, 2024 Exhibit 99.1 is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (Registration Nos. 333-223915 and 333-270477) and its Registration Statement on Form F-3 (Registration No. 333-264190).

2 SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Â SOL-GEL TECHNOLOGIES LTD. Â Â Date:Â November 20, 2024 By: /s/ Eyal Ben-Or Â Â Eyal Ben-Or Â Â Chief Financial Officer 3 EX-99.1 2 exhibit\_99-1.htm EXHIBIT 99.1 Exhibit 99.1 Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement NESS ZIONA, Israel, November 20, 2024 (GLOBE NEWSWIRE) - Sol-Gel Technologies, Ltd.Â (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEOÂ® and EPSOLAYÂ®, today announced that it has received an extension of the period to regain compliance with The Nasdaq Stock Market LLCâ€™s ("Nasdaq") minimum bid price rule. Â OnÂ November 19, 2024, the Company received a letter from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or untilÂ May 19, 2025, (the "Second Compliance Period") to regain compliance. Nasdaq's determination was based on (i) the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and (ii) the Company's written notice to Nasdaq of its intention to cure the deficiency during the Second Compliance Period by effecting a reverse stock split, if necessary. In order to be provided with a Second Compliance Period, the Company submitted an application to transfer the listing of its Ordinary Shares from the Nasdaq Global Market to the Nasdaq Capital Market. This transfer to the Nasdaq Capital Market was approved and became effective as ofÂ November 15, 2024. Â If at any time during the Second Compliance Period, the closing bid price of the Companyâ€™s Ordinary Shares meet or exceedÂ US\$1.00Â per Ordinary Share for at least ten consecutive business days, Nasdaq will provide written confirmation of compliance and this matter will be closed. Â The Company intends to continue to actively monitor its compliance with the Minimum Bid Price Requirement and, as appropriate, will consider available options to resolve any deficiencies and regain compliance, including the implementation of a reverse share split, if necessary. Â About Sol-Gel Technologies Sol-Gel Technologies, Ltd.Â is a dermatology company focused on identifying, developing, and commercializing or partnering drug products to treat skin diseases.Â Sol-GelÂ developed TWYNEO, which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older, and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults. Â The Companyâ€™s pipeline also includes a Phase 3 clinical trial of Orphan and Breakthrough Drug candidate SGT-610, which is a new topical hedgehog inhibitor being developed to prevent the new basal cell carcinoma lesions in patients with Gorlin syndrome that is expected to have an improved safety profile compared to oral hedgehog inhibitors as well as topical drug candidate SGT-210 under investigation for the treatment ofÂ rare hyper-keratinization disorders. Â For additional information, please visit our new website: Â www.sol-gel.com

Forward-Looking Statements Â This press release contains â€œforward-looking statementsâ€ within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to theÂ Companyâ€™s ability to regain compliance with the Bid Price Requirement and to maintain compliance with any of the other Nasdaq continued listing requirements and the timing and effect thereof.Â In some cases, you can identify forward-looking statements by terminology such as â€œbelieve,â€ â€œmay,â€ â€œestimate,â€ â€œcontinue,â€ â€œanticipate,â€ â€œintend,â€ â€œshould,â€ â€œplan,â€ â€œexpect,â€ â€œpredict,â€ â€œpotential,â€ or the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our managementâ€™s current expectations and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, a delay in the timing of our clinical trials, the success of our clinical trials, and an increase in our anticipated costs and expenses, as well as the following factors: (i) the adequacy of our financial and other resources, particularly in light of our history of recurring losses and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; (ii) our ability to complete the development of our product candidates; (iii) our ability to find suitable co-development partners; (iv) our ability to obtain and maintain regulatory approvals for our product candidates in our target markets, the potential delay in receiving such regulatory approvals and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; (v) our collaboratorsâ€™ ability to commercialize our pharmaceutical product candidates; (vi) our ability to obtain and maintain adequate protection of our intellectual property; (vii) our collaboratorsâ€™ ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; (viii) our collaboratorsâ€™ ability to establish adequate sales, marketing and distribution channels; (ix) acceptance of our product candidates by healthcare professionals and patients; (x) the possibility that we may face third-party claims of intellectual property infringement; (xi) the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products;

[illegible]

M.BR7\$C[Y97<\*R X=XSZ?.;9SXB\6Y'X@X#.,WX7R B3'Y?P]G&55W5KX3"8"  
MK\_9\_ML7D6)J8;"3AC:U"KF'ML!/"5\+0KK"?4<5.E&3\_+KX]^#Y9/L-K=>,/\$W\_"2>'UN99(H[W4[\_.,7K6OB  
M#1M(MD:2Z,.EWGC35?+3R(:[FPS?L=X&\<^\$?B5X1V/^//>OZ?XH\(>\*=  
MM]6T'7=,D:2SU"QN5RDBB18YX)HV#P75G=107MC=136=[;P74\$T\*?TSP?XB< M&\>8?  
V\_"V>X7,9QY\*M6P4HU<)F6'IWA&4Z^78RG0QD\*<\*DXTW75&6'=22C"K  
M\FBW^FY7GN4YRI\_V;C.:JG22=6BFX5Z2;LG.C-1J\*+>BGRN#?PR>AU=%%?: MGK!1110!\_&G  
,'(D.OK^U9\_#I[A+\>%Y/V>[6'1Y)%G&F-K\Q'\>/XD2T= MA]F:\_CTZX\\*M]\*Q\$SK;R:6;@\_"[4M]I?\*\$?  
^"@/P!TK]G[2/V2/B9XP\-" M[XD>!\_%/B"X\$W'B[4].VZ%\3=&\=^)KC7+>UT?7M1N;6RG\N?  
#;:VRZ[:>'\_T\_ P""F'\_!/KPÿ\_P\_%/@K9>%HM8M?""Q= M^'=UJGB#X\A C. BDFT>TU35+6U@UOPGXK2WM;S4%\',  
(.TJ/5;S1X7U?1 M=4TC0/\$%M:ZW;Z1=^&->\_B\_)\_:,\_8\_-:T\_95U/4[;XR\_!/QIHNA:=)\OQ!T?2 M[CO1\,  
[^WDGO(.XM?'N@1W\_(C9"/^ M"L7\_45^']A%IVA?M6?\$6\_MX<.);&\VA?XF7YP2?WNJ?\*\$?P\_P"\*]3GY/)FO M),C"G@  
\_T0:VA^/P2/\$?M&\_" +QM\%\_B+;W,\_A/QQIL%G>RV+6\>I:9??: MJ%GK6A:[I,MW;7EK%J\_A\_7M-TW6M+DN;2ZMEOK"#  
[1;7\$'F0O\_&#VO^" \_\ M\_P  
%!O!D)-5^\$/Q: +QK&LWC\_X:OZ9+"RMEIXO^%6:Q\&8?. B[KNF^" \_VA?!H\_LZZ[JEQ:6&G^, \_P"W%\9\_"V>\  
MG:.\_WW:]K\*Z7HFN>"(KB[EC\$5QJ&CZSX>(/%FE6ML9ÿ\_#^@NC-06US\_M;WMM;WEG<07=I=P17-K=6TJ3VUS;3QK+!  
<6\3/%-!.\$ZR12QLTG^&ECJ-KYGT\Z3X);\$]A?6,7CAM;TN\BU#28#0!\\_!2#\_@N\X(UWQ\ M#\_V))&U37=%OI]&\5?  
M!W]K8^(!LK^S,\\_HZ?\*= %NTNM%\0R6EZL5NWCK M7X=4\,W2V^HQ>' \_#VMV5WI'BZ+Y/\_8O\_  
."3/[1'\_!1%=\_.\_A\_:3^./Q,T3X M?>+HHKWPQ=:YJMQXE^,GQ\*\_,C?8]6T2\7-J^G^?!\$P=^\*7VIZ1K\_U;3+ M+=G0\_"\_F/\_  
,\$U?V:WU#PAX"TB\_7ZIH%Z(KNRN(;/Q?)H]KX-GO+6<7-@/\$(OH5=[<?\* \\_1@@A  
MAMH8;:VABM[>WBC@@@C6\*&"&)'!%##%&%2.\*.%5(XT541%"J\_!0!^9?@+\_M((Y?\\$Y?  
%E:V]K^SAHGBF][MX8KG5\_'OB;QKXQO=2FCMQ!)>W5GJ\_B\*;0; M>XN?FGFBTG1M-L\$N',EM9VX6-4Q\_B1\_P1:\_X)S?  
\$;3=3M5^R>-6OK6\@M/\_M\$WPW\8^,?#6I:)/=J0+\_ \$S1YM:U+P5-=6DFV:SAUKPGJ^G1,@C:PDMFE@D\_  
M5&B@#^('JO3\_(?)#?7]@>= VB/V=\_'GBKQS\("E'[J\_P#PF&AW-SX9^,7P\_MMJ\_A;PQIUk:~AJ7OG\_!. M\_P#X+P^/?  
VJ^'?A%^VIJ%W\0?A\_ =3Z5HFD?'\$0++X\_\$1%8M.CN/B\_ENJGX\_M@>';<+;76I>(/\*X6!:\*6U2\_N?'=Y=6MA:?  
U[:CIVGZOI]JL.K6-GJFE:I9\_MW6G:GIFHVL-[I^HZ?>P/;7EC?6=RDMM=V=W;2R6]U:W\$+=1:KY\_[L-  
1TZ\_M))K6]L;VUFBN;2[MI9;>\_MYMY8YH9'C=6-UE5U9'4,C\_JRL\_RLK###RG((!!&"\_#7X"?&]W[2\_B#XN?  
MLQ>\_O@CXMU/4=:U;]F\_Q/H=CX'M/\\*>+/\_6\_!&OZ?X>TFWBL]\*TN\ \\_#VGV?C7XQ: MY\1= =\?  
^)!;0MK&N3>%B/XU!\^';"?43'JL.CZ-H7ANV.FZ29C866H:AK>H  
MVT\$5YK.HRW\SG\;3\_E)U^TS\_W1G\_UGWX45\_51\_P1+\_ .48O[,W\_=9O\_6@O\_MBO0!^JE%%%!1110\_4444  
%13SPVT,UQ<2QP6]O%)///,ZQQ0PQ(9)999'(5\_M(XT5G=V(55!8D\_\$U+7PY\_P\_+%+\_MWX\*\_8#\_:VUJRB\$L]S\O&7A?  
&2#'\_#XYL M?^\$)N;E&!!62TMO\$,UU\$P.5DA4CD4\_?Q,\_\!2G]M\_Q)^W^TCXE\<+J6J1  
M"+PA=ZCX4^"/A2YFN([+2?!=K=^6?\$TNE!/\_Q6GBCQ\_+\_P^(\_\$LLT,VI6R/I\_M'A:~4M0TOPIHKO\_T,?)  
!!G]@#PY\OA5IG[9WQ\*\VU\_P#%;XH6VHI(EU2\_M'2:3X??#&1YM+DU\_3K2ZMHHK#Q3\13%?3#6[FR7?@\_P  
47&G#4KKP%X\_TZ"X?PGXVTV!+FPNGGT:\_E,>I\_M65GJ6F2:]X=O-;,\W-] %INMWP?  
Z;BCCACCAAC2\*&)\$BBBB18XXXXU'I^B@\*\_MB(H"HB@\*J@\_4^B@\_K^+^A\_X.)OAGX.\'?M:~#3QIX9T33M\$U;XF?""+4O&  
MATRRM;)->O:#XKU[2XO\$FI?9XHW0-;N]'DTW2;R^N&DEFLM\$TQ&.Z%F?^TR\_MOX\?^#DS\_DX7]G?\_+(SK\ZF^IT  
>1?;\$2/V\$?V(/"V+\_A,\_P#A:\_\;WVC^PKVS^W?:?A%-\_%K[5\_MYGV;R)?(V?:)MW[R?.\_(P#@G!\_T2WQG\_P"8^('P\_NZ\_-  
[\_@V7\_P;)\A\_MNV[\_-]W7]5%\_X)\. (P#@G!\_T2WQG\_P"8^('P\_NZ\_/C\_@H#\_P\_\$'?@O\_MX(^!WQ\$^-'[\*>K>/M\$6\_#?  
P>^\_,[\_X8>(M67QCX:~3^%\_#EI/]B6R\,7,F\_MFKXOTSQ\$'L=UJNF?:M6]2V>LW.FP^'8=^TV;5AK-  
C\_2M2/B7X!^#\_@CQ#\_M2/B?XMT3P/X&\*;?+J>O>?)\$5'L=9=8VT>%1\_SYEN[V[F:.STW3+\*\*YU+5=0  
MGMM.TVTN[^YM[>3+^"WQ,LOC1\OA3\8=,TN\T33/BM.\!/Q(TW1M0EAGO)\_M\*T\_QQX:TWQ-8Z?  
>S6W^CRW=I:ZG%!9':(LA4D\_W\_/A6W)"^!?!?@F\_MS\*FT'\>\$O#GA6U\*\*\*0VWA[1/2("B@\*%4Q6:[5\_P!TK?U/3--  
UO3;\_1M9\_MTZQU?2-5L[G3M4TK4[2WO]-U+3[V%[>L+^QNXy;6\L[NWDD@N;6XBD@GA=X\_MI4=&93>HH\_S-?  
VNO"/A[P!^UA^T]X#(\Z9!HOA/P3^T-A:O"/AC1K7?JFTG\_MP[X;^)/B71M%TRWWLS^18;:96UK%O9F(N)=S\$Y-?W@?@\$K?  
A3X&^%['![-5\_MKX)T.STJ3QS\."/WQ\\_%];6J:GXC9^/](M[\$>MZMK5]!!#<:I<O->PZ) MI4M]Q<:~X;TG1-  
#AF^PZ7:1Q\_PQ\_MV?GO?MD?G5?M#? \JW/%]?WQ?[\$] M?^3\$ \_P!C[\_LV\_P"#O\_J"Z+0!B4444\_%%%"\_DGQK^!7PI\_:  
(\#7GPY^,/A"MQ\8^%+NYMKY;2YFO;"JT\_4K-\_M-3TC5]+N;+5=\*OX#N0W%A>0&XM9BQNQ<  
M6%U=6LWXO\_\$;\_@A]HNGR37WP-^\*TK1\_VHMO#/Q4LHVD!07\_M8]G:\_P#"#+\_RS@GU#[UT/W[HKZ;(>,>  
(^&TX93F=:AAY3]I!U#%\$8.\*OV?BI\U#?#XB>!M1T:UDDC\_MCMM:@\$&J^'KMY&F\$,4&OZ7)>:~6+R5+6:8:;/=0ZI'  
%FFLH5= "WWC\_P3N^\$9\_M;XY6GBQ;6:U"^-3<75GJ^JW=M!ZM/J MMW)\$K\_9G\*\_MCXQ9PHN@WTGCW4?  
#MAX;NX)K\*\_3Q/I>E7\$]3B:PF@U(\_M9\_[3#O0V/ES-! MYFC:##);VT=K!IUMJNM02:X-M7^V7EI;\_V5?00W&HW\_-  
FNX[:6&"#F\2\_I\_M<>!"!/"V:X#Q%XGR+AC.,9@G1HX6&+EBL;B\+B\$H8FK2R#" 7<^DOJSFH2P^  
M\$Q=\*4YPBZM.4Z<9\_E.5>5'(N,&Q<'BX474DZ>'JTHQTIUKRE#4/^"@]CKWP?\_:=^+6CZ\ES%;^\*?\$NJ\_M?\$3P[?  
RVTUI:ZKH'CB^N]=BFTZ27Y;R#2]0NM1.75S\_7A.J:)]\$'R20NB?F\_MAJ/CC5M?U""2- LM1UK5KZ58++3-  
'M+G4M00)Y'1(XK6RM(YKFXFDD95CCAB\_M9V=@J@D@]X\_VH\_C6W[5%OH&G\_\$/X;?#Y).\ZK-J\_AB3^R]J\_U[3];B-HKJ  
MTDUVZN]]SIFHQI:-JVC?8X=\$U>?3=,N;\_3IYM.LF@^98[\*'3+";2M&M+'0M( MGN&NY-\$VZ?9:#H?VIQA[A-  
%T>WLM+BE?G=)%:H6)9B268U\_@'Q[X]>'\_%C#\_MB#\ Y9FF>Y3F.9XO,  
<)7SB\$/K2Q52C3I7S'&8FAA\*M65'E/\$1P5:O3\_MAVBA\*4]C^JS?PZQ>\_S/%U?[%/EE>%\_M.LO;MP<:DZ7-S4S[R](^  
/QC\77%O-XFMK?X;Z'+)\*+R[5S\*OB\*!;>95N;6\_M/P):2R^\*H=5>'>^F0^ (K#PWH]]((TGUZPMY?M:T"?(!\_!+CXL2?#  
[XE1\_L]V\_MKWS^O&&@D>+&6[8SW%IXO!\_!AF&2?7KEQ,MK:S^\*\_#N@ZC-XA2VA:&;6+?  
M18;:SM\_+;X\*N[/\_ZU=VVC(D1Z3#>R?7.E%NLI?'9Q/A5XO)\_%LO&PSS##5,/@\*\_+B\* M,K>6993JX?  
#8K+\^Q^%RG,VBI5\*F)K8NMBX6R\_ABLIY>L36Q->116(Q>+J]KB\*L%>+H4U3IT:-&BW.4E3A2YY2<'6JU\_MG2I-?  
U\$T445\_O"?I\_4444\_!YX(R#P0>]?@\_X"X\*&\_#W]EO\_@I!^U]^R#]? M/%&C^#/AGXK^(7A'XF\_"WXAZ">S66@^\$?  
&'Q\$^%/P\2>+\_"?BO6+^Y\_LS0O\_M#&O7FHQZ]I&JW\$6EZ3H'B%O\$ \_P#;6I7-MXBL)M'\_>21)426)UDCD57CD1@  
MZ.C@,CHZDJRLI#\*RDA@002#0!X)XZ\_92\_9>^\*~&KR^(/B3^SA!\\_'B">W%I+MX@\_9\_" +P!XFUUK8;]D(UG6?  
#]YJ:I&9':)=+Y3L7CVN=U?+?BS\_())\$?\$X\_MO&?"WQ-\6O@EK\$MA';Z39:=XAM?'W@BRO8W);4  
M=1T3QK9WGC'4VF1BDEM;?;\$2+<%8WA\$1\$@E\_E\_\V[OV!?'C^P-\2=.\&?\$F\_M?2?\$OA;Q>FLZC\\_-B-  
X=6ZBT7QEHEVCWL%O=I<6%Z@N]\4Z5;ZAHTOB7PW)-\_MJ;&DS:M:+IVN:]IL]J]W\_HUU\_\*;\_P\_"GQ^&^FMQ\_  
\_JG+0M7TO7?B9X/U\_M6?B+XYM;"1;FY"Z5JFA6^E^&M&UBXCC:&SU3Q9%>76N?V)]J74[72-)T;6-\_M2L(-.10>'+N  
/L+\_@WQ\_:)2\_%C]E+QE(O%VIW^LZA^SWXTL=\$,7U)](9W\_MM?AOXSTR75/"\_A\_[5--+=W']@:WI'C&UL%FV6^F^9-  
T/3DCLM^BAB^5\_\M@YBT;5)M+\_\*8X\OQVTKZ-IVH?'1KR\8P6VIZU;'\*\*^TRVD/W5EOK30-6EA'\_M5TT^?LE?  
57!\_OG^SKXC^\$W]\*B\_XO>+=.O=(U'JH?QG9:YX:L+V-X'G^&\_@O\_M3I)]+Z:]I;/P75NVOZVJOC'^L=IKD40#7\_  
CNMZ2(UKJBR2?H#\_P4=8Y\_ML\_VX?V6O%\_P>M[JTTSQUIE[9^/OA/K.HS7D.F:9!\_#EIJ5MI<6K&TD!&D^ (MM'U?  
7?";I74UM]:.:>(9-?MM\*O]2TBQ@(!)\_Q\_P03\5Z7X= P""B7@O2M0" M\_?'/PW^\*A31682?)JEOX?'C-MK(I1&?  
2O".J1\*9BD;&3RU8SR0H\_\=I7^M9#X>U;XP\_L@?M!Z]KLFE:KV\_C/\B%INJR:'KUO=6EQIWB+PQJ\_-V^DZU:

M07%L] H>KPH;/4K:&Z.G^(?#NHS11W%SiFHB27\_0R\_8Y:~^[:GP9T'XM  
M##5+9;F:VM+3QsX)EOHKGQ#.O%K6X?4?#.00B.WG\*Q3K,^C:P;VL\_\$6E"" M5;!%BE>& ^K\*\*\*\* "OXA\ @X9\5>'?  
\$/[>FBZ1HE];W>I^!?!V?OAYX5\7V M\WS.-,17GB?X@^-[ :QN]IS]HD\)>,"^I+OPwV34+7 V;?"[ OVD\_VDOA-^ MRA\  
( \_\$OQF^,GB.'0?"V@0M%96<;0RZ\_XN\0S03RZ1X.(:7)-"^L^")M;,>WE2 MSLT>\*VM+6&JUG6+O3- TO5M5L?/\5^ (GB?  
XV \ !0;]K;Q3XIT+PCJOC'XO M?'[Q[/X/?\\$\*%OY;"\$S\$=EX>!.07TL5A;P^'O G@[2]/TRZ2:R=/L=-\> M'YM?  
17UG:6VH7L8!\_0- P+SV@ZK%68?MB^\*;74(=#OKOX%Z#I]Z4==\*U:M=\*A^+&H:O:QR%?  
+GU#1K36=#EF16WVEMKT#.H6]C) J=KXD\_X)[ \_+>C?L/ M\_LQ^#?@O;3V.J>,9I;CQE\5\_\$FFS7D^G^)/B7K]K8Q:  
[=Z8]]!93'1-'LM.T MGPIX>D;3-)GN]!VZ=J.I.;!K-[J;2 \_;= '\ ?\ P6T\_Y2=?M, ]T9\_9]^% M%?U4?\\$2\_P#E&+^S-  
\_W6; UH+XKU\_\*O \_%M/^4G7[3/ =&? 6?^A17]5' ! M\$O\ Y1B\_LS?JUF\_J]:"^\*] 'ZJ4444 %?'G[??  
@#X^\_%]'DKXL>!/V7\_\$>M>\$ MOCGKO\_""?\"(X/A\>-KWX,M/O=O.'^U^#]/\06- MQY-Y#\_:%K6".WT3PGX1T'7?  
%/B35;j:&WL],TLVEK]MU[4M#T; M5?1J /X/?^& O^""^?\_1QOQF\_\39\9\\_S;4?\\!?!% \_^CC?C-\_XFSXS\_P#F  
MVK^PZB@#%O^"7]L/\ P4X^"O[0^C#Q3^VC6/B!X]^%M\_?'\\$'\_A\_0=(\5\_MM\$>  
(/BWIUMX^NO&OP^U'2]2A\.:KXAU:WLKV'P[I7B]UCUM+9)K:"\N+!9U3 M4I(Y/UC\_&MOA)??'G]F#X\_  
;TB&PFU\_XC?"/QYX8\++JMQ):.9'XOO\_#M M^/"%QJ-U#;W\*UN98H(7>."5U""Z&HH\_RM[NTN]/N]JPO[  
M6XLKZR\K2]LKN"6VN[2[MI&AN+6ZMYE2:WN+>9'BFAE1)(I\$:-U5E('E1^ MQ5\;+ \: \_9/^ 'QDM[ZSU"]\9?  
# 'PS+XGEL(WAM+);QUH]BGA\_X@:9!%(S2 M1QZ3XVTK7],0.S92T5U9T96\W7\_6T\_P""6GB;0?%WC+JM3]GWP]<:YX\*\  
M2R7?B?X^>IM\$L?.U/P7XA?=<:[\5=\*LK1/U'PCX@;S-9\?(9K\_+;ZVJ^ M+[R>Z\;MJDG@WYD\_P""O\  
P5&T\_P#8XU[4\_@=<[<V];]G?Q]K:ZU8Z\_#S:M:C<";QK=Q6UC>ZZ;2TBEU\*^'\>  
(;6ULH\_\$FG6<=Y<:5>6%MKNBV'G77B&'5 MP#^X"BL3PWXE\>,M T?Q7X0U\_1?%7A?  
Q%IUKJ^@>)]/FJ66MZ#KFE7T2SV6 MIZ1J^FSW-AJ5A=PNDUM>6=Q;SQLKQ2,I!K;H \*^-/VQA^V;HO@+7?'G[(GB  
MOX3R:]X\^\*ZEJ\\_PI^)7P[UK7KGQ]=Z6+C4I[7PUXUT?QMHRZ%KEWID3Z?HF MBZEX9U#3-7UO[%#?>  
(O#EG<7.H6\_V710!\_%\_P1#'[>O\_0(^'\_(:SQ)\_\ MW]?U\$?L+:U^VK\0\_AMX1^+\_[5OBOX164'Q\$%Z7XGV\_I'^?  
PU\0Z%K?AN\_MS\1VFFZUH=[XL7Z]XTOR:-72KEX=5(VGA2--\*O)@DOB\*[FMYK5/Z2O]37 MPT /#F@\_#1.\* & +& #@  
#H\*-NOX?^#DS\_DX7]G? LC.L \J;ZG M7]AU?QX '\)G\_)PO[ \_&1G6?\\_U-]3H ^./^"5' !.S\_AOK\_A?/\_%]/\$\_P  
M6\_X5/ PJ[ \_D7/#O]O \\_2\_)W\_PL3\_C\XJCPW]D\_L;\_A#?]'\_X\_?/\_+5G\_M\_P'/?R?W\_P'O?\_\$\_Q\_U?  
1\3O\_#=\_C/KS'\_@V7\_YO8\_[MN\_]I[W7]5% '\B'[ M5W\_!'QM\./@MX^++'@7]J#5?BUK'PQ\):[XS?P'XP\  
W>DZSWI.@6CZOXAN\_ MT#Q!:'^/\$K6VL\_V+874NEZ4WAZ:/7-3@M.DU'31.MU#\_4U\"O# #^"/@A]&  
M!E:]K@76;GPQXKN/#\_F-J.D:3 MXMTW7/'YU-HH+>\_U30-3N-\*]HKZ;JVH^AT?YK/[=G\_>] ^V1\_V=5^T-\_Z\_MMSSQ?  
7]!\7\_DQ]/C[\_+O^#O\_\*@NBU\_[^W9\_P GO?MD?G5?M#?^K<\ M7U\_?% P3U\_Y,3\_8^\_P'S;\_@[\_P"H+HM 'V)1110  
45[\_]' +J]/PC\#+WPQH- MYX6?]?\$CQMXMM=9U?2?A]\+-(T?7O&/\_BWAR72[/Q!XRN['7/\$/AFPMO#. MD:MX@\\-  
:)=7;:F;N75/\$6FPV5C=PIJ5QIY0!]\$5\^?M!?'&?\_ (5/X=@ATB." M[\7Z\Z:/!<\*9;>PMH-  
JW6L7D2D"18'ECBL[:1T%W=,S8E@M+N.OH.0RP\_:6 MO9];^+'B,23>=!I,>FZ18J)],6W@MK"">>!"E4?VE=7\TD8  
\N>:5!?'<3\_M "/J-7QFSKP5%<3FW%#>6#XFXJSS '\9-F<.5U\$Q:4\_8.\$08R3\_QQ^,<])J"\*5>4>D^64(1@\_)RFFU2:Z  
MGR)XVUGQ)XRU2YUSQ3K&HZJ]EPS;[O4;AYV1"[. (+9#B&TM8RQ\$%G:QPVMNF M(X(8T\_4>2ZAI!8A<>AQ]>"/?  
OZ8^E>[7VGYW?+USQCTS[#G\_/17%:AIH(;Y\_M/KQ]?;G\^A\_/\_6.>8S,,77Q^8XW\$X\_'8RM/\$8O&8S\$5<5BL57JR#!\*L/7/  
M'^>];\1Q6+ =;3KA(IH);U: !H4EK)\*83P]N?^CO@\_I+ \_P3D^\_VJ7WC.Y^ M.FNZ?+;:!X;L]4T;P3<3^;  
=6\1:G!+I.L:C8J&7[5IVD:/J>DW\$TD;VDVI M:H8K662]T:\_2UJW^\$G\_![PSHMS::U\7M=;"8"EEU9PQF\$P M-  
\*O5Q[S'A1>,C@8X65#&<\$<-'VBG+  
[+O%>V;TZ;Z/>VRNG&+>SOM%ALO\$O@>\*6P\Z>FN:HUKX^\$CO+=V.@PNK6\\_P"=/@+]  
MEG\_@O3^PLD ACX':W<\_\$3X;Z/#&EKH\_AWQ[X^)?P\CLK1KJ\\_-GX2\"\_&"32\_M?%OAJ.YN+ZZENXO""A3P[>:G=!3<-  
I;2>&?^":FKV,8-PMT^J?LR\_M3^(\$N&5TCC%L^G\_MZ]X>6V,#QW"7\_D-X979%7[.8'\$W]2-%\_JNM^\_  
O^#AS]K;3XK71/AW[-7@\_MOQ1;FPU!]\$M/'P2U#2+6X0;]0EN\_B#XFUSX^++^+B%9%F\RV^KPOGR8/,B MD\*>R?LB?  
&\\_7A;PGXJLOBI^VK\1K7XW>+DUB[U^Z^&OA.69/A]JFLR7U\_-M0\  
<>,\_\$=MIOC'XA1W[S6>M7VE#1?!MN^L13V.NW/B\_0[B]M;\_P#I&HH\_KV=G  
M::?.6MA86MO8V%C;P6=E96<\$=M:6=I;1+#+;6MK;0JD-O;V\*)%!!\$B111(L<M:JJ@\"Q110!^?';W\_!-  
+JFO]NK2TO/B+HEUX4^\*>EZ9)IOACXQ>\"Q:6/C#3K\_M=6\$]IIFOPSQ2Z9XT\\_-P72AET?  
7[>6[TZVN=4C\+:QX9N]6O;^3^>:Z\_X(^?\\_M%0/V( \_B5\_P\_+) \_8P^).E>/IH'DL['7OA]XITCX?^\*.0T119W\$EIX\_P#AW\3+  
MVW\\$\_ZMID^H\*94(-?))0M-G?3K74+F\"&6VAA\_L@HH\_F2^'\\_P4Z\_X+?\_M#ZZN/#?QK\_XJ]>/\_ (MRZ+;VVFG6O  
OP=^\_WA#4-2O[99%O-4O\Q)X?T/XD M>\_M;[N@=&=]:%HVDQ.D\_P]G#QRI';=-X\_E\_X<[\_]%;OB/?;X6^"7\_!+WQM\  
M.]8U07=K)K'Q:!!?%[6;:\_2VG\FZMM?U[1O@OX\W\W]\_ES0S^KS4M.GFB\_M6"6TE\$PA\];/10B]  
'C/CZR^ (W[=WQJTCX>650+=0V^FZUK\_M.E^H/M>\-V,]K9JT/@#X9?#>[MOA5XO[BZA35]5T]6M3\_M\$SS?  
O]^QC\_P3P\_9I\_8:T\*:#X0^%9M2\=K82Z=XG^+GC)K/6/B-XALI[R^E\_MTK^U8+\*QLM \\_.: +73S\_ (YX9T\_2-  
+O&TG2K[6H=7UNS\_M>7[FHH\_\*Y+QUX\_MDU?PCX5U7Q#H/@/Q9]3=6T\67V3P/X'NO!5EXHULW6HVEE,-  
,NOB)XP\!>#H\_MAIUO^\_L?0?#7AK1?!OAJQN;X\_\$RW%\_J47\_MAWP[I?\\_M];6L%YJ9N[FWM+6"6.WC^L?V7/'W\_  
7V\_9(^#VA\_WX;?LU?\_M#G6/7A>\_P!B@#^<\_P#X79\_P<6?]&F\_?\_P<\_\"K\_.B0\_MJ\*?XT?\\_IQ?;-!%^RI\# +626\*2-  
+F#6/A&T]N[H56>%;G]HJXMFEA8B2,7%\_MO/74"6&6/) MM#^\$EY?C3X:ZKI\_A[Q;XHN](T&6#P?X1^%WB/4]\$-  
:=%X%N/&=GJF=\*TZ/\_M4KO6TU"ZDU+6);B]3^B\*BB@\_HHHH\_\*\*\*\*\_\\\$9IX(/>OQ+\_&Q\_ ^"&[+7]  
M2FHZCXW^%UQZ/:Z9?LMN\_M0EYX\*UKPI;2W5[J&J:YI?B#4;@3)^VE%\_\"= \_@[\_]\_P#!:\_S]@/6[F3]EO\_MQE;>\_  
\_,K7EY>:3\OB%X:U?P)>BXXFMWFN=6^\$WQJBV:>WB>ZM+=LX)M5T' MPWJ>M6D\$LFgz3XD\*:X:3Z-)?) !4G\_ (+  
(^&[QM\B+\_P35]5>-K?30MC\_M<7/AC]GG]HOPOJ%[<67QGX;O%N@A:\*XT;1;?36+\"YM!+:O"7] M0=%  
'R'BC\_@J]\_P5QUAK+ \_A7\ P2\9^\"(YY8BTGC'X%\_M^>-8)X)HE\"&\* MZTFV^'-O:]TS";  
[7\UNEN=K\*;YKSCQEV\_ \_#A#]L@2^&\_&= \_;?L\ \_#KQ(0 MUU9Z9XP!\_ \"G0K.SNK>ZM[C3M6E^'VH^\*\_CC>Z/2,E?  
ZMJ\*\_YC\_ -FW\_@W%)\"Z#:A\?A+9W'AG\_MPK+>VUY#/U\"U26RNO[%]-?  
#K7D67;VL,5O!'N9MD,\*+ '\$FYV9VVHJKN=F8XRS\$Y-344\_5+^YEL[\"JO( M+\"[U2>TM+FYATRP:R2\_U&6\"%Y8[\"R?  
4KS3].6[O'46]LU\_?V-DLTB&ZO+:\_2\_M3)\_A\_P5'\_9#\_P\"D[/?7[0.D?\$/PC^QsXD&?#SP/X)M/ G@W2O\$ \_QD\_9UD  
M\1ZE\"FM:SKVI>)=QUG7+2UL]&LIEU.:>ZN53^M\_MJB@#^\_7]CG]E+\_@MU^PO)0W^!/[. 'A>W7XH)X43Q7#XL\;?  
+Q%'\_W@MO\$9\_MT&6R)^+ME-9/\_%>M+.\$E\_:Y6XB\,M;PLOV\_P#\+7\_X\_.O^C%-3\$M:KV;?  
P+X;URS;3];MOA=XT\_9Q\':IJ=G(X:6W;Q3%\3KWQ;IL5PH^SWD>AZ\_M[I<=]9O-8WJW%G<7\$ \$O]65%  
'S!^Q7\\$/^&]626.ZCU#Q[J\_B/4!/\_YMY/M1:V\"P&-5]1\_M^+GC?QGx'\7.N^?@]XR^'.B;;  
<:\_K]HVIV]U8>%M7@@O/L\_IU%\_\"(GQC\_P\"3G\_!M4?XR\_%WXJ?%\_5\_V54TK5?BK2/'\"Q(U/2['XP?\_J6RTW4//B?5/\$]  
[86(O@E>:;|^'=+3[/HVE7-YHGQUT\"SNX='T)(-L[B73\_M\_M]MI:PMJ%W?7AFNY?ZAJ\*  
/YS\_P#A=G\_IQ9\_T;:\!\_P#P<\_\"K\_P\"B0JCJ7QA\_MX\_][ZPN[I\_U\_9@\"^NC7%Q\4J;Z]OP8EO[!V'%S:1ZQ^T!JNEO-'U1;[3;VW  
M)^\_XXK^CZB@#\"(O^\"4[?\*\_ [?:A+X] M&?M1\_M^Z;X@/QD/9>#\_\"?P[!ZYK\_MWCKP5XJDN/'=\_KVI>\*\".F:?  
I'P]O:QX:\+Z%9:MH'@0Z-HUK::196);4H] M&TZUMYKSSROW=HH\_\*\_?X^Z/JC^\*7BH&\$QQW2:XT=YGFAN  
M(E#D#^S+J>XDG\"1\$M:WD]Q-\*D5CAOXC^G]X7Y[XF>\_6+GPU@J^99SP+Q%EW&

ML,MP=&5?'9AEN#P.:93G%#!TH1E4JU,-@5Z>5RI48U:\J5\*?TG M"V+HX7-(QKR4:>\*HSPW-)VA&E35--  
Z)SO\*RNU^>EGX7U7Q#J-O MH^BZ;=:IJ5XY2VL[.%III2 2SD\*N(XHD!DGFD\*0V\2O--)'\$CN/J+P/^Q>]\ MD6H?\$C6Y+  
\Y\>'7@ENU4QQLBWVMSQSV<4J2F6\*XMK"RO8GC59+?5E:0B/ MZX^&'PUTGX0Q/KNK  
%Y;JZQO:W@E=4=-.M7)CM852(J"XFC M-S+(Q],K\H^CI^SVX/X;R;\*N)O&NE/BOBW%X>AC9\ (1Q-7#\, \2JPC5A@\Y1;  
<5YIX.^#GPP\!-%+X6\%:'I]]"TC1ZM+:\_ VCK:&9 M DH36M3:\U2..11AH(KM+<9;;\$H9@?  
2Z\*\*\_T[37NPC':\*2^8E\*4WS2E\*3>[DVW][U" MBBBO7)"BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\*  
"BBB@ MHHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "BBB@ HHHH \*\*\*\* "B 5BB@ HHHH \*\*\*\* "BBB@ HHHH  
\_\_9 end